Literature DB >> 319204

Naloxone-induced reversal of schizophrenic hallucinations.

L M Gunne, L Lindström, L Terenius.   

Abstract

In a single-blind pilot study 0.4 mg naloxone i.v. was found temporarily to reduce or abolish auditory hallucinations in four cases of chronic schizophrenia whereas saline was without effect. In one of these patients there was a similar reversal also of her visual hallucinations. Two additional cases who denied hearing voices before the injections, reported no subjective effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319204     DOI: 10.1007/bf01250276

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  19 in total

1.  Search for an endogenous ligand for the opiate receptor.

Authors:  L Terenius; A Wahlström
Journal:  Acta Physiol Scand       Date:  1975-05

2.  An endogenous morphine-like factor in mammalian brain.

Authors:  G W Pasternak; R Goodman; S H Snyder
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

3.  Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine.

Authors:  J Hughes
Journal:  Brain Res       Date:  1975-05-02       Impact factor: 3.252

4.  THE ANALGESIC EFFICACY AND RESPIRATORY EFFECTS IN MAN OF A BENZOMORPHAN "NARCOTIC ANTAGNOST".

Authors:  L LASAGNA; T J DEKORNFELD; J W PEARSON
Journal:  J Pharmacol Exp Ther       Date:  1964-04       Impact factor: 4.030

5.  Levallorphan; effects of large doses.

Authors:  M SWERDLOW
Journal:  Anaesthesia       Date:  1958-07       Impact factor: 6.955

6.  The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.

Authors:  L LASAGNA; H K BEECHER
Journal:  J Pharmacol Exp Ther       Date:  1954-11       Impact factor: 4.030

7.  Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone.

Authors:  D R Jasinski; W R Martin; J D Sapira
Journal:  Clin Pharmacol Ther       Date:  1968 Mar-Apr       Impact factor: 6.875

8.  Opiate receptor: demonstration in nervous tissue.

Authors:  C B Pert; S H Snyder
Journal:  Science       Date:  1973-03-09       Impact factor: 47.728

9.  Identification of two related pentapeptides from the brain with potent opiate agonist activity.

Authors:  J Hughes; T W Smith; H W Kosterlitz; L A Fothergill; B A Morgan; H R Morris
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

10.  Increased CSF levels of endorphines in chronic psychosis.

Authors:  L Terenius; A Wahlström; L Lindström; E Widerlöv
Journal:  Neurosci Lett       Date:  1976-10       Impact factor: 3.046

View more
  24 in total

1.  Opioid peptides, brain and behaviour: a brief review.

Authors:  R J Rodgers
Journal:  Ir J Med Sci       Date:  1978-08       Impact factor: 1.568

2.  Endogenous ligands of opiate receptors.

Authors:  H Teschemacher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

3.  Cortical opioid markers in schizophrenia and across postnatal development.

Authors:  David W Volk; Polina V Radchenkova; Erin M Walker; Elizabeth J Sengupta; David A Lewis
Journal:  Cereb Cortex       Date:  2011-08-01       Impact factor: 5.357

4.  Effect of naloxone on the state of patients with endogenous psychoses.

Authors:  R R Lideman; G P Panteleeva; F E Vartanyan; B S Belyaev
Journal:  Neurosci Behav Physiol       Date:  1984 Nov-Dec

5.  Opioid peptides as neuroregulators: potential areas for the study of genetic-behavioral mechanisms.

Authors:  J D Barchas; S Sullivan
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

6.  The effects of naloxone on methylphenidate-induced mood and behavioral changes: a negative study.

Authors:  L Y Huey; D S Janowsky; L L Judd; N A Roitman; P L Clopton; D Segal; L Hall; D Parker
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

7.  Clozapine inhibition of metenkephalin binding to synaptosome-enriched fractions of rat whole brain and hippocampus.

Authors:  E Somoza; C Franco; M Laviña; J A Fuentes
Journal:  Neurochem Res       Date:  1981-04       Impact factor: 3.996

8.  Negative naloxone effects in schizophrenic patients.

Authors:  D S Janowsky; D S Segal; A Abrams; F Bloom; R Guillemin
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

9.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

Review 10.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.